

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

ESPERION THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
- Fee paid previously with preliminary materials.
- Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Your **Vote** Counts!

ESPERION THERAPEUTICS, INC.

2026 Annual Meeting
Vote by May 27, 2026
11:59 PM ET

ESPERION[®]

ESPERION THERAPEUTICS, INC.
3801 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108



V91143-P42641

You invested in ESPERION THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the 2026 Annual Meeting. **This is an important notice regarding the availability of proxy materials for the 2026 annual stockholder meeting to be held on May 28, 2026.**

Get informed before you vote

View the Notice, Proxy Statement and our 2025 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 14, 2026. If you would like to request a copy of the material(s) for this and/or future annual stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 (toll-free from the U.S., U.S. territories and Canada) or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote Virtually at the Meeting*

May 28, 2026
8:00 AM ET

Virtually at:

www.virtualshareholdermeeting.com/ESPR2026

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review the proxy materials at www.proxyvote.com before voting.

Voting Items	Board Recommends
1. Election of Class I Directors Nominees:	
1a. J. Martin Carroll	☑ For
1b. Sheldon L. Koenig	☑ For
2. To approve the non-binding advisory resolution on the compensation of our named executive officers.	☑ For
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.	☑ For
4. To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.	☑ For
NOTE: The proxies are authorized to vote on such other business as may properly come before the 2026 annual meeting of stockholders or any adjournment or postponement thereof.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".